Canada markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
100.41+1.16 (+1.17%)
At close: 04:00PM EST
99.83 -0.58 (-0.58%)
After hours: 07:31PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close99.25
Bid99.83 x 800
Ask101.91 x 900
Day's Range99.28 - 103.41
52 Week Range88.00 - 188.99
Avg. Volume632,914
Market Cap24.075B
Beta (5Y Monthly)0.24
PE Ratio (TTM)5.27
EPS (TTM)19.04
Earnings DateNov 06, 2023
Forward Dividend & Yield2.11 (1.32%)
Ex-Dividend DateJun 02, 2022
1y Target Est140.34
  • Yahoo Finance

    AWS expands big pharma partnerships in manufacturing, AI, and R&D

    Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.

  • Reuters

    CORRECTED-UPDATE 1-European Patent Office declares Moderna mRNA patent invalid

    The European Patent Office declared a contested mRNA patent owned by Moderna invalid, the office said on Tuesday, handing a win to BioNTech and its partner Pfizer in a patent dispute between the two coronavirus vaccine makers. Moderna said in a statement that it disagreed with the office's decision and would lodge an appeal. Shares in Moderna were down 2.3% in premarket trading on Wall Street after the decision was announced by BioNTech earlier on Tuesday.

  • Reuters

    BioNTech says European Patent Office has declared Moderna patent invalid

    COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer. "We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," the German biotech firm said in a statement. "The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted," it added.